<DOC>
	<DOCNO>NCT02802852</DOCNO>
	<brief_summary>Neovascularization ( NV ) innate capability enlarge collateral artery ( `` arteriogenesis '' ) , stimulate growth new capillary , arteriole venule tissue level ( `` angiogenesis '' ) . Patients Chronic Limb-threatening Ischemia ( CLI ) present forefoot rest-pain , ulceration and/or gangrene . They require risky costly revascularization operation avoid amputation . The investigator hypothesize inadequate NV modulate restore capability . By correct impediment NV out-patient setting , investigator expect facilitate CLI management . While follow impediment NV complex , solution . Arteriogenesis necessitate endothelial cell activation small collateral blood offload away occluded artery . Shear stress provide stimulus , attenuate caudal multi-level arterial occlusive disease . The `` arteriogenesis switch '' turn . Furthermore , lack nutritive oxygenate blood inflow accumulation toxic metabolic by-product adverse synthetic pathway ischemic tissue . Additionally , protein `` distress '' signal effectively disseminate ischemic tissue , reparative progenitor cell suppose mobilize effectively home back ischemic tissue orchestrate NV . The CLI patient especially disadvantage diminished function number circulate progenitor cell ( CPC ) . Lastly elderly , often diabetic , patient less able fend infection . An FDA approve external program pneumatic compression device ( PPCD ) use restore shear stress stimulus require arteriogenesis . It also enhance oxygenated nutritive arterial inflow , clear waste product metabolism ( increase venous lymphatic outflow ) , help distress protein reach central circulation mobilize progenitor cell return ischemic tissue . We correct progenitor cell immunologic impairment granulocyte colony stimulate factor ( G-CSF ) , FDA approve stem cell mobilization immunological boost set cancer chemotherapy . The preliminary data show clinical , angiographic , hemodynamic biochemical evidence enhance NV . The purpose study enroll 25 patient reproduce biochemical data support large scale clinical trial .</brief_summary>
	<brief_title>Proteomics Stem Cell Therapy New Vascularization Strategy</brief_title>
	<detailed_description>Twenty-five CLI patient ischemic forefoot rest pain , non-healing forefoot ulceration , dry forefoot gangrene recruit . They already undergo standard care evaluation , include hemodynamic testing duplex ultrasound delineation arterial anatomy Non-invasive Vascular Laboratory . Those tibial artery occlusive disease , normal correct proximal aorto-ilio-femoral arterial anatomy , give option enrollment lieu surgery catheter revascularization . The standard vascular assessment data review : History Physical ( H &amp; P ) examination , vascular laboratory hemodynamic data ( arterial duplex imaging , ankle toe pressure ) , blood test ( complete blood cell count , metabolic lipid panel , hemoglobin A1C diabetic ) . Carotid duplex scan , chest X-Ray , electrocardiogram , chemical cardiac stress test , echocardiogram review available . While angiography magnetic resonance imaging ( MRI ) , compute tomography ( CT ) catheter may available , require . Data obtain in-clinic use LUNA fluorescence angiography may also collect , necessary . To emphasize , ultrasound , x-ray , CT , MRI LUNA fluorescence data may collect since image standard care patient evaluate peripheral vascular disease , specific imaging require image studied part protocol . PPCD use continue present symptom resolve traditional revascularization becomes necessary achieve limb salvage . Each patient serve his/her control . Three `` pair '' blood specimen analyze per patient . A `` pair '' include phlebotomy prior immediately two hour PPCD . The first pair obtain enrollment study . The second pair do 2 week later 18-24 hour last dose G-CSF . The third pair do 30 day study , 18-24 hour last dose G-CSF . The patient return standard care clinical evaluation , repeat hemodynamic testing , 6 month 30 day clinic evaluation . Case Report Forms ( CRFs ) prepare subject . Progression ischemic symptom result discontinuation participation trial immediate standard care treatment , include image study revascularization , indicate . Otherwise status present forefoot symptom ( ischemic rest pain , ischemic ulcer , gangrene ) document Day 1 , Day 14 , Day 30 . Ischemic rest pain score ( 1 10 scale ) . Pain free walking distance measure . Forefoot ischemic lesion photograph dimension record enrollment . Baseline visit ( Outpatient Care Center ) : 1 . Patents undergo standard care H &amp; P examination . 2 . Upon verification patient eligible ( base inclusion/exclusion criterion ) , informed consent form explain patient good explain study ask authorization participate . Baseline visit ( Non-invasive Vascular Ultrasound Laboratory ) : 1 . Other standard care test include : duplex ultrasound ( DUS ) , ankle toe pressure , yet complete prior clinic visit . Day1 ( Clinical Resource Center , University Illinois Chicago ) : The following procedure do order : 1 . Initial blood draw ( 20 ml ) 2 . Patients wear PPCD seat position ( 2-hour session ) . 3 . After 2-hour use PPCD , another blood draw do ( 20 ml ) . 4 . Each patient give Neupogen shot ( 10 mcg/kg ) subcutaneously 5 . Patient give ample time fill quality life ( QOL ) questionnaires ( SF36 , EQ5D , VascQoL-6 ) study coordinator available time assist patient . Each questionnaire take 10 minute fill . 6 . Blood sample send Dr. Bartholomew , MD Lab analysis . Days 4 , 7 , 10 , 13 ( Home clinic ) : The following procedure do : 1 . Nurse PI administer Neupogen shot ( 10 mcg/kg ) subcutaneously , every 3rd day , total 10 Neupogen shot . Patient continue use PPCD every day , least 3 hour day , till symptom resolve . Day14 ( Clinical Resource Center , University Illinois Chicago ) : The following procedure do order : 1 . Initial blood drawing ( 20 ml ) , 18-24 hour 5th shot Neupogen . Blood sample send Dr. Bartholomew Lab biochemical analysis . 2 . Patients wear PPCD 2 hour seat position . 3 . Just prior end 2-hour use PPCD , another blood draw do ( 20 ml ) . 4 . Patient return empty vial Neupogen . 5 . Patient give ample time fill quality life ( QOL ) questionnaires ( SF36 , EQ5D , VascQoL-6 ) study coordinator available time assist patient . Each questionnaire take 10 minute fill . Day30 ( Clinical Resource Center , University Illinois Chicago ) : The following procedure do order : 1 . Initial blood drawing ( 20 ml ) , 18-24 hour 10th shot Neupogen . Blood sample send Dr. Bartholomew Lab biochemical analysis . 2 . Patients wear PPCD 2 hour seat position . 3 . Just prior end 2-hour use PPCD , another blood draw do ( 20 ml ) . 4 . Patient give ample time fill quality life ( QOL ) questionnaires ( SF36 , EQ5D , VascQoL-6 ) study coordinator available time assist patient . Each questionnaire take 10 minute fill . 5 . Patient return empty vial Neupogen . Monthly Follow-up ( Clinical Resource Center , University Illinois Chicago ) : 1 . After completion initial 30 day treatment period , patient follow-up clinic 1 month interval ongoing clinical assessment . The patient continue use device alone daily wound heal forefoot rest pain resolve . 2 . At 6 month visit , patient fill QOL questionnaire . Each patient follow total 6 month . Repeat hemodynamic test occur Intersocietal Accreditation Commission certify non-invasive ultrasound laboratory 6 month visit . Unscheduled visit early termination : 1 . Enrolled subject give contact information principal investigator access study organizer question concern arise home in-between clinic visit . Patients wish terminate enrollment study contact principal investigator manner .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Male female age 35 85 . 2 . Chronic limb ischemia Fontaine Class III ( ischemic forefoot rest pain ) Class IV ( nonhealing ischemic ulcer , gangrene ) confirmatory noninvasive vascular testing . 3 . English Spanish speaking patient 1 . Acute limb ischemia require emergency treatment . 2 . Nonsalvageable foot ( e.g . extensive gangrene , advanced infection , rigor mortis , knee/hip flexion contracture , poststroke paralysis , hemiparesis ) . 3 . Untreated hypercoagulability disorder , sickle cell anemia , myeloproliferative disorder . 4 . Dialysis , and/or sustain elevated Creatinine &gt; 3.6 mg/dl . 5 . Severe dementia ; bedridden ; noncompliance ; unlikely followup ; unreliable . 6 . Intolerance PPCD compression 7 . Morbid obesity ( Body Mass Index &gt; 34 ) 8 . Severe venous insufficiency cause venous stasis ulceration dermatitis . 9 . Uncorrected significant aortoiliac , common femoral , profunda femoral arterial disease 10 . Ulceration preclude PPCD placement . 11 . Active cancer . 12 . Allergy Neupogen . 13 . Uncorrected symptomatic coronary artery disease 14 . History lymphoma leukemia</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>